GLP-1 drugs like Wegovy alone do not work, may benefit more from a combination treatment, a recent review of the evidence ...

Indian women are turning to GLP-1s to treat symptoms of the hormonal disorder which has limited treatment options.

Days after semaglutide, the molecule behind blockbuster weight-loss drugs, went off patent in India, prices dropped sharply ...

The skyrocketing popularity of GLP-1 receptor agonists has transformed the weight-loss industry, but not all shots are ...

The thriving market in online, counterfeit GLP-1 drugs that do not meet FDA criteria poses serious risks to consumers.

In a study, people with gene variants in two genes lost slightly more weight on GLP-1 drugs, but threw up more on Zepbound.

Clinical trials suggest that about 10% to 15% of people who try GLP-1s don't lose weight. But evidence is building that shows ...

The largest published prospective evaluation of off-label targeted cancer therapies has shown that more patients could benefit from existing drugs.

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again.

Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.